Akari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research note issued to investors on Saturday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Up 3.3 %

Shares of Akari Therapeutics stock opened at $1.00 on Friday. The business’s fifty day simple moving average is $1.61 and its 200 day simple moving average is $2.71. Akari Therapeutics has a 12 month low of $0.90 and a 12 month high of $4.40.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.